Lumen Bioscience Announces Issuance of US Patent for Genetic Modification of Spirulina

by admin | Jul 23, 2020 | Press Release

Seattle, WA—November 26, 2018—Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, announced today that the US Patent and Trademark Office has issued Patent no. 10,131,870, entitled “Targeted...

Dr. Craig Behnke Joins Lumen Bioscience as SVP, Production and Development

by admin | Jul 23, 2020 | Press Release

Seattle, WA—July 9, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that Dr. Craig Behnke has joined its executive team as Senior Vice President, Production and Development. Dr. Behnke will assume...

Lumen Wins Triple Funding Boost to Advance Development of Low-Cost Therapeutics for Newborns and Infants in Developing Countries

by admin | Jul 23, 2020 | Press Release

Seattle, WA—June 13, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that the Bill & Melinda Gates Foundation has tripled its funding commitment for Lumen’s ultra-low-cost antibody therapeutics...

NIH Awards Grant to Lumen Bioscience for Cost-Effective Oral Malaria Vaccine

by admin | Jul 8, 2020 | Press Release

Seattle, WA—May 21, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that National Institutes of Health (NIH) will fund continued development of its ultra-low-cost, recombinant oral malaria vaccine. This...

Lumen Bioscience hires executive to scale blue-green algae technology

by admin | Jul 8, 2020 | Press Release

Read More